



Announcement Summary

Entity name

AMPLIA THERAPEUTICS LIMITED

Announcement Type

New announcement

Date of this announcement

16/4/2024

The Proposed issue is:

A standard pro rata issue (including non-renounceable or renounceable)

Total number of +securities proposed to be issued for a standard pro rata issue (including non-renounceable or renounceable)

ASX +security code	+Security description	Maximum Number of +securities to be issued
ATX	ORDINARY FULLY PAID	77,602,558

Ex date

18/4/2024

+Record date

19/4/2024

Offer closing date

8/5/2024

Issue date

15/5/2024

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

AMPLIA THERAPEUTICS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ABN

Registration Number

16165160841

1.3 ASX issuer code

ATX

1.4 The announcement is

New announcement

1.5 Date of this announcement

16/4/2024

1.6 The Proposed issue is:

A standard +pro rata issue (non-renounceable or renounceable)

1.6a The proposed standard +pro rata issue is:

+ Non-renounceable



Part 3 - Details of proposed entitlement offer issue

Part 3A - Conditions

3A.1 Do any external approvals need to be obtained or other conditions satisfied before the entitlement offer can proceed on an unconditional basis?

No

Part 3B - Offer details

+Class or classes of +securities that will participate in the proposed issue and +class or classes of +securities proposed to be issued

ASX +security code and description

ATX : ORDINARY FULLY PAID

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

No

If the entity has quoted company options, do the terms entitle option holders to participate on exercise?

No

Details of +securities proposed to be issued

ASX +security code and description

ATX : ORDINARY FULLY PAID

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

ISIN Code for the entitlement or right to participate in a non-renounceable issue (if Issuer is foreign company and +securities do not have +CDIs issued over them)

Offer ratio (ratio to existing holdings at which the proposed +securities will be issued)

The quantity of additional +securities to be issued

2

For a given quantity of +securities held

5



What will be done with fractional entitlements?	Maximum number of +securities proposed to be issued (subject to rounding)
Fractions rounded up to the next whole number	77,602,558

Offer price details for retail security holders

In what currency will the offer be made?	What is the offer price per +security for the retail offer?
AUD - Australian Dollar	AUD 0.05500

Oversubscription & Scale back details

Will individual +security holders be permitted to apply for more than their entitlement (i.e. to over-subscribe)?

Yes

Describe the limits on over-subscription

The Entitlement Offer incorporates a Shortfall Facility under which Eligible Shareholders can apply for Additional New Shares up to a cap of 100% of their pro rata Entitlement. The issue of Additional New Shares will be dependent on there being a shortfall in the take up of pro rata Entitlements under the Entitlement Offer.

Will a scale back be applied if the offer is over-subscribed?

Yes

Describe the scale back arrangements

In the event the Shortfall is less than the number of Shortfall Shares applied for by applicants, scale back will apply to applicants under the Shortfall Facility. The scale-back among those Applicants will be considered and determined at the Board's discretion, in consultation with the Lead Manager, taking into account the total Shortfall, the number of Shortfall Shares applied for and each Applicant's current shareholding.

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Part 3C - Timetable

3C.1 +Record date

19/4/2024

3C.2 Ex date

18/4/2024

3C.4 Record date

19/4/2024

3C.5 Date on which offer documents will be sent to +security holders



entitled to participate in the +pro rata issue

24/4/2024

3C.6 Offer closing date

8/5/2024

3C.7 Last day to extend the offer closing date

3/5/2024

3C.9 Trading in new +securities commences on a deferred settlement basis

9/5/2024

3C.11 +Issue date and last day for entity to announce results of +pro rata issue

15/5/2024

3C.12 Date trading starts on a normal T+2 basis

16/5/2024

3C.13 First settlement date of trades conducted on a +deferred settlement basis and on a normal T+2 basis

20/5/2024

Part 3E - Fees and expenses

3E.1 Will there be a lead manager or broker to the proposed offer?

Yes

3E.1a Who is the lead manager/broker?

Taylor Collison Limited

3E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

The Lead Manager will receive:

- (i) an underwriting fee equal to 4.0% of the gross Entitlement Offer proceeds less that part of the Entitlement Offer proceeds that is taken up by, or sub-underwritten by, a Director;
- (ii) a management fee of 2.0% of the gross Entitlement Offer proceeds; and
- (iii) 3,500,000 unlisted options, each of which is exercisable for one New Share at an exercise price of \$0.135 and an expiry date of 5 June 2028.

3E.2 Is the proposed offer to be underwritten?

Yes

3E.2a Who are the underwriter(s)?

Taylor Collison Limited

3E.2b What is the extent of the underwriting (ie the amount or proportion of the offer that is underwritten)?

100%

3E.2c What fees, commissions or other consideration are payable to them for acting as underwriter(s)?

The Lead Manager will receive:

- (i) an underwriting fee equal to 4.0% of the gross Entitlement Offer proceeds less that part of the Entitlement Offer Proceeds that is taken up by, or sub-underwritten by, a Director;
- (ii) a management fee of 2.0% of the gross Entitlement Offer proceeds; and



(iii) 3,500,000 unlisted options, each of which is exercisable for one New Share at an exercise price of \$0.135 and an expiry date of 5 June 2028.

3E.2d Please provide a summary of the significant events that could lead to the underwriting being terminated

Refer to investor presentation dated 16 April 2024 which is available on www.asx.com.au

3E.2e Is a party referred to in listing rule 10.11 underwriting or sub-underwriting the proposed offer?

Yes

3E.2e (i) What is the name of that party?

Robert Peach

3E.2e (ii) What is the extent of their underwriting or sub-underwriting (ie the amount or proportion of the offer they have underwritten or sub-underwritten)?

149,999.96

3E.2e (iii) What fee, commission or other consideration is payable to them for acting as underwriter or sub-underwriter?

Nil

3E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?

No

3E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer

N/A

Part 3F - Further Information

3F.1 The purpose(s) for which the entity intends to use the cash raised by the proposed issue

Pre-clinical studies (cancer), Phase 1 (Pilot Investigator Initiated) clinical trial - Ovarian Cancer, Phase 2a clinical trial - Pancreatic Cancer, Drug capsule manufacture, IP and licences, Cash costs of the Entitlement Offer and working capital.

3F.2 Will holdings on different registers or subregisters be aggregated for the purposes of determining entitlements to the issue?

No

3F.3 Will the entity be changing its dividend/distribution policy if the proposed issue is successful?

No

3F.4 Countries in which the entity has +security holders who will not be eligible to participate in the proposed issue

Canada, Liechtenstein, Singapore, Spain, Swaziland, Switzerland, United Kingdom, United States of America

3F.5 Will the offer be made to eligible beneficiaries on whose behalf eligible nominees or custodians hold existing +securities

Yes

3F.5a Please provide further details of the offer to eligible beneficiaries

Nominees and custodians may not distribute any part of the Offer Booklet or any Entitlement and Acceptance Form in any country outside Australia or New Zealand, except to beneficial holders of Shares in Australia or New Zealand, and beneficial holders of Shares who are institutional or professional investors in other countries that the Company has approved as being a country in which investors are eligible to participate, as well as any other country to the extent the Company may determine it is lawful and practical to make the Entitlement Offer.

3F.6 URL on the entity's website where investors can download information about the proposed issue

<https://www.ampliatx.com/site/news-and-reports/ASX-Announcements>

3F.7 Any other information the entity wishes to provide about the proposed issue

3F.8 Will the offer of rights under the rights issue be made under a +disclosure document or product disclosure



statement under Chapter 6D or Part 7.9 of the Corporations Act (as applicable)?

No

3F.9 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)